Research Demonstrates Scope of Unmet Need in PBC New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term Risk of Liver Transplant and Liver-Related Death NEW YORK, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, today announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that will be presented at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver...
↧